Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Hematologic Neoplasms × ivosidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2 Recurrence 1 Myelodysplastic Syndromes 1 Leukemia 1 Hematologic Neoplasms 1 Cholangiocarcinoma 1

Interventions

talquetamab 2 ivosidenib 1 fedratinib 1 enasidenib 1 Midazolam 1 Itraconazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Servier

Phase 1 Recruiting

291 enrolled 3 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡